Compare Baxter International Inc (BAX) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Morgan Stanley — how do they compare? Baxter International Inc trades at $27.81 (market cap $14.36B), while Morgan Stanley trades at $216.18 (market cap $338.50B). The key difference: Morgan Stanley is far larger — about 23.6× Baxter International Inc's market cap, and Morgan Stanley pays the higher dividend (2.14%). Which is the better fit depends on your goals.
| BAX | MS | |
|---|---|---|
Market Cap | $14.36B | $338.50B |
Sector | Health | Financials |
52-Week High | $28.35 | $228.42 |
52-Week Low | $15.80 | $143.88 |
Enterprise Value | $21.88B | — |
Dividend Yield | 0.14% | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
Morgan Stanley (MS) trades at $216.26, up 1.18% with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $66.0B in 2025, with net income margin expanding to 25.56%. The stock is supported by analyst consensus price target of $239.58 and recent news of leading Anthropic's IPO, indicating robust business momentum.
Outlook remains positive given earnings growth and institutional support, but risks include volatile cash flows and high debt levels. The stock offers upside to consensus targets, though investors should monitor interest expense impacts and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
